Enviaments recents

Metabolic dysfunction-associated steatohepatitis reduces hepatic H2S-producing enzymes altering persulfidome composition

SHEN, TZU-KENG; Vignane, Thibaut; Gilglioni, Eduardo Hideo; Traini, Leonardo; Kalaitsidou, Elisavet; Conan, Pierre; Herranz Alzueta, Jose Mari (Data de publicació: 2025-10-30)

Steatohepatitis; Metabolic dysfunction; Persulfidome

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer

Karta, Jessica; Meyers, Marianne; Rodriguez, Fabien; Koncina, Eric; Gilson, Cédric; Klein, Eliane; Alonso Landeira, Lidia; Aguilera Pujabet, Mònica; Nuciforo, Paolo (Data de publicació: 2025-10-30)

Fusobacterium nucleatum; Cancer-associated fibroblasts; Colorectal Cancer

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

Winkelmann, Michael; Raj, Sandeep S.; Müller, Fabian; Hansmann, Leo; Jain, Michael; IACOBONI, GLORIA; Barba, Pere (Data de publicació: 2025-10-29)

Metabolic prognostic index; CD19 CAR-T; Large B-cell lymphoma

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Martini, Jean-Francois; Pasquina, Lincoln; Tunquist, Brian; Zhang, Xiaosong; Khaiser, Fatima; Yaeger, Rona; Tabernero, Josep (Data de publicació: 2025-10-29)

BRAF inhibitor; Colorectal cancer

White paper on best practices for translational research in neuroendocrine neoplasms

Cros, Jerome; Casanovas, Oriol; Castaño, Justo P.; Dayton, Talya; GIBERT, Benjamin; Garcia-Alvarez, Alejandro (Data de publicació: 2025-10-29)

Carcinoids; Genomics; Liquid biopsy

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Huang, Min; Haiderali, Amin; Fox, Grace E.; Frederickson, Andrew; Cortés Castan, Javier; O’Shaughnessy, Joyce; Fasching, Peter A. (Data de publicació: 2022-09-09)

Triple-Negative Breast Cancer; Economic burden

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab

Elez, Elena; Calleja, Elizabeth; Caussé-Amellal, Nadia; Fakih, Marwan; Ciardiello, Fortunato; Prager, Gerhard (Data de publicació: 2025-08-12)

Adverse event; Metastatic colorectal cancer; Safety

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

Zampini, Matteo; Riva, Elena; Lanino, Luca; SAUTA, ELISABETTA; Antunes dos Reis, Rita; Andrés Ejarque, Rosa María; Acha, Pamela (Data de publicació: 2025-09-05)

p53 dysfunction; Myelodysplastic syndromes

Presence of Ceramidase Activity in Electronegative LDL

Puig Calvó, Núria; Rives, Jose; Estruch Alrich, Montserrat; Aguilera-Simón, Ana; Rotllan, Noemi; Camacho, Mercedes; Colome Calls, Núria; Canals Suris, Francesc (Data de publicació: 2023-02-27)

Ceramide; Sphingomyelinase

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

Blumberg, Stefano B.; Battiston, Marco; Kakkar, Lebina S.; Lin, Hongxiang; Grussu, Francesco; Ianus, Andrada (Data de publicació: 2022-06-16)

Brain; Protocol design; Quantitative MRI (qMRI)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Tolaney, Sara M; Loirat, Delphine; Hurvitz, Sara; Cortés Castan, Javier; Rugo, Hope; Bardia, Aditya; Punie, Kevin (Data de publicació: 2022-10-27)

Breast cancer; Drug safety

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

Osterlund, Emerik; Sjöblom, Tobias; Hammarström, Klara; Nunes, Luis; Mathot, Lucy; Mezheyeuski, Artur (Data de publicació: 2025-08-12)

Primary tumour; Molecular alterations; Metastatic colorectal cancer

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

Villanueva Cardús, Josep; Bellio, Chiara (Data de publicació: 2021-11-10)

Càncer de mama triple negatiu; Autofàgia; Resistència terapèutica

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective

Sessa, C.; Cortés Castan, Javier; Conte, P.; Cardoso, Fatima; Choueiri, T.; Dummer, R.; Tabernero Caturla, Josep (Data de publicació: 2022-07-22)

COVID-19; Cancer care; Clinical research

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Li, Qing; Jiang, Baishan; Guo, Jiaye; Shao, Hong; Del Priore, Isabella; Chang, Qing; Palafox Sánchez, Marta; Serra Elizalde, Violeta (Data de publicació: 2023-04-20)

Proteïnes supressores de tumors; Inhibidors de la quinasa

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Chi, Ping; Somaiah, Neeta; George, Suzanne; Blay, Jean-Yves; Jones, Robin; Serrano, Cesar (Data de publicació: 2024-10-25)

KIT mutations; Gastrointestinal stromal tumor; Targeted therapy

Unlocking the potential of engineered immune cell therapy for solid tumors

Albarran Fernandez, Victor; Urbano-Ispizua, Alvaro; Guedan Carrio, Sonia; Angelats, Laura; Delgado, Julio; Gros, Alena (Data de publicació: 2025-04-01)

Immune cell therapy; Solid tumors

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Davis, Elizabeth J; Martín Liberal, Juan Jesús; Kristeleit, Rebecca S; Cho, Daniel; Blagden, Sarah P; Berthold, Dominik; Vieito Villar, Maria (Data de publicació: 2022-11-28)

Inmunomodulación; Linfocitos T; Microambiente tumoral

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Ring, Alistair; Kilburn, Lucy; Pearson, Alex; Moretti, Laura; Afshari-Mehr, Angelica; Wardley, Andrew; Llop Guevara, Alba; Serra, Violeta (Data de publicació: 2023-12-20)

Olaparib; Ceralasertib; Triple-negative advanced breast cancer

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Gillessen, Silke; Turco, Fabio; Davis, Ian; Fizazi, Karim; James, Nicholas; Efstathiou, Jason; Mateo, Joaquin (Data de publicació: 2025-03-04)

Adjuvant therapy; Biochemical recurrence; Bone protection

Articles científics - VHIO: Enviaments recents

Metabolic dysfunction-associated steatohepatitis reduces hepatic H2S-producing enzymes altering persulfidome composition ﻿

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer ﻿

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma ﻿

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer ﻿

White paper on best practices for translational research in neuroendocrine neoplasms ﻿

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review ﻿

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab ﻿

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes ﻿

Presence of Ceramidase Activity in Electronegative LDL ﻿

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging ﻿

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer ﻿

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort ﻿

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer ﻿

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective ﻿

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors ﻿

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations ﻿

Unlocking the potential of engineered immune cell therapy for solid tumors ﻿

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors ﻿

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) ﻿

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) ﻿